drugset / Trial / NCT04903158
Relative Bioavailability Study of SHR3680
RandomizedParallel-groupOpen-labelBasic science
Summary
This is a single-center, single-dose, randomized, open-label, parallel sstudy to evaluate the relative bioavailability of new and old formulations of SHR3680 tablets in healthy male subjects under fasting conditions.
Timeline
- Start
- 2021-01-06
- Primary completion
- 2021-03-15
- Completion
- 2021-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezvilutamide | Small molecule | 240 mg | Oral |
Indications
No indication recorded.